4.7 Article

Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-Induced Endocrinopathy: A Prospective Study

Journal

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 107, Issue 7, Pages 1976-1982

Publisher

ENDOCRINE SOC
DOI: 10.1210/clinem/dgac161

Keywords

immune checkpoint inhibitors; endocrine-related adverse events; autoantibodies

Funding

  1. CTSI Clinical Scholars Grant under the NIH National Center for Advancing Translational Science (NCATS) University of California Los Angeles Clinical Translational Science Institute (UCLA CTSI) [UL1TR001881]
  2. National Institutes of Health (NIH) [T32DK007770]

Ask authors/readers for more resources

This study prospectively evaluated the impact of endocrine autoimmunity on the development of immune checkpoint inhibitor (ICI)-induced adverse events (ERAE) and overall survival (OS). ERAE occurred in 14 patients, with hypothyroidism being the most common. The presence of antibodies was significantly associated with ERAE. The presence of ERAE was associated with a more favorable OS.
Context Incidence and awareness of endocrine-related adverse events (ERAE) associated with use of immune checkpoint inhibitors (ICI) has grown with increased ICI use, yet mechanisms for ERAE prediction, surveillance, and development are not well established. Objective We prospectively evaluated the impact of endocrine autoimmunity on ERAE development and overall survival (OS). Methods Adults >= 18 years of age prescribed ICI treatment for advanced or metastatic solid tumors and no known active/past endocrine disorders were eligible for enrollment. Thyroid, adrenal, and pancreatic antibodies as well as hormone levels were assessed prior to ICI treatment and at 8 to 9 weeks and 36 weeks after treatment for ERAE in relation to presence and changes in endocrine-specific antibodies, hormone levels, and OS. Results Sixty patients were enrolled and ERAE were detected in 14 (23.3%), with a median onset of 52 days (IQR, 38.5-71.5) after first ICI dose. Hypothyroidism occurred in 12 (20%) patients, and 2 (3.33%) patients developed hypophysitis. Diabetes and primary adrenal insufficiency were not observed. Antibodies were detected in 14 patients (11 at baseline, 3 developed during follow-up) and their presence was significantly associated with ERAE (R-2 59.3%, P < 0.001). Thyroid peroxidase antibody (20%) and thyroid-stimulating immunoglobulin (3.3%) were most common, and anti-GAD was present in 1 patient. The presence of ERAE was associated with a more favorable OS (P = 0.001). Conclusion Endocrine-specific autoantibodies play an important role in ERAE pathogenesis and may serve as predictive markers for early identification and treatment of ICI-induced endocrinopathies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available